In the early 1990s, more than 10 years before the serum AQP4-IgG and MOG-IgG were measured in patients with ON, a landmark clinical trial of the Optic Neuritis Treatment Trial (ONTT) was performed (42, 43). This evidence concerns the gene AQP4 and optic neuritis.